Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Recruiting
Phase 1
Phase 2
Interventional Study
Neovascular (Wet) Age-Related Macular Degeneration
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- Eyconis INC. · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
* Willing and able to comply with clinic visits and study-related procedures
* Provide signed informed consent
Exclusion Criteria:
* Known hypersensitivity or known al…
Contacts